Details of the Drug

General Information of Drug (ID: DMME6GJ)

Drug Name
SB12
Indication
Disease Entry ICD 11 Status REF
Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [1]
Drug Type
Antibody
Cross-matching ID
PubChem CID
84703
TTD ID
D2RTQ0
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Paroxysmal nocturnal haemoglobinuria
ICD Disease Classification 3A21.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C5 (CO5) DTT C5 7.69E-01 -0.12 -0.23
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04058158) A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria. U.S. National Institutes of Health.
2 Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019 Sep;18(9):707-729.